Cronos Group (CRON) vs Definium Therapeutics (DFTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Cronos Group (CRON) over the past year, gaining 193.1% versus a gain of 23.7%. Over five years, DFTX leads with a -0.5% price change compared with -40.9% for CRON. Definium Therapeutics is the larger company by market cap ($4.71 billion vs $1.19 billion), about 3.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | DFTX |
|---|---|---|
| Share price | $3.24 | $35.09 |
| Market cap | $1.19B | $4.71B |
| 1-day change | -1.37% | -1.49% |
| YTD return | +23.19% | +162.06% |
| 1-year return | +23.66% | +193.15% |
| 5-year return | -40.88% | -0.45% |
| P/E ratio (TTM) | 17.05 | — |
| EPS (TTM) | $0.19 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-183.79M |
| 52-week high | $3.61 | $49.70 |
| 52-week low | $2.28 | $10.47 |
| Distance from 52-week high | -10.20% | -29.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | -24.07% | +104.19% |
| Average volume | 1.14M | 2.15M |
| Shares outstanding | 368.41M | 134.37M |
| Employees | 610 | 105 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Definium Therapeutics is about 3.9 times larger than Cronos Group by market value ($4.71B vs $1.19B).
- DFTX has outperformed CRON by 169.5 percentage points over the past year.
- The two companies sit in different sectors: Cronos Group in Healthcare and Definium Therapeutics in Health Care.
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Healthcare · Drug Manufacturers - Specialty & Generic · 610 employees
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
CRON vs DFTX FAQ
Which is bigger, Cronos Group or Definium Therapeutics?
Definium Therapeutics (DFTX) is larger, with a market capitalization of $4.71B compared with $1.19B for Cronos Group (CRON).
Which stock has performed better over the past year, CRON or DFTX?
DFTX returned +193.15% over the past 12 months, compared with +23.66% for CRON (price return, excluding dividends). Past performance does not predict future results.
Are Cronos Group and Definium Therapeutics in the same industry?
No. Cronos Group is in the Healthcare sector, while Definium Therapeutics is in Health Care.